Kiniksa Pharmaceuticals International, plc
KNSAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Kiniksa Pharmaceuticals International, plc focuses on Drug Manufacturers - Specialty & Generic services and products. Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The $6.01B market capitalization puts KNSA squarely in mid-cap range for its industry. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Market Cap
$6.01B
Beta
0.09
P/E (TTM)
77.87
P/E (Fwd)
47.66
EPS (TTM)
$0.99
EPS (Fwd)
$1.62
ROE
14.0%
ROA
8.1%
Cash
$525.9M
Total Debt
$8.9M
Free CF
$126.1M
52W Change
111.4%
Annual Financials
Cash vs Debt
Where KNSA stands vs its 150-day and 200-day moving averages
As of the August 18, 2026 close, KNSA finished 49.14% above its 150-day moving average ($53.09) and 58.17% above its 200-day moving average ($50.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KNSA overbought or oversold?
At the August 18, 2026 close, KNSA's RSI(14) was 49.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kiniksa Pharmaceuticals International, plc holds $525.9M in cash against $8.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $126.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 14.0%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $220.2M (2022) to $677.6M (2025), reflecting a 208% increase over the period.
With a beta below 0.7, Kiniksa Pharmaceuticals International, plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, KNSA has financial flexibility that may help navigate uncertain periods. At over 50x earnings, KNSA carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kiniksa Pharmaceuticals International, plc's trajectory.